

## **Product datasheet for TL316446V**

#### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

### Serum Amyloid P (APCS) Human shRNA Lentiviral Particle (Locus ID 325)

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

**Product Name:** Serum Amyloid P (APCS) Human shRNA Lentiviral Particle (Locus ID 325)

Locus ID: 325

Synonyms: HEL-S-92n; PTX2; SAP

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

**Components:** APCS - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

**RefSeq:** NM 001639, NM 001639.1, NM 001639.2, NM 001639.3, BC007058, BC007058.1, BC007039,

BC070178

UniProt ID: P02743

**Summary:** The protein encoded by this gene is a glycoprotein, belonging to the pentraxin family of

proteins, which has a characteristic pentameric organization. These family members have considerable sequence homology which is thought to be the result of gene duplication. The binding of the encoded protein to proteins in the pathological amyloid cross-beta fold suggests its possible role as a chaperone. This protein is also thought to control the

degradation of chromatin. It has been demonstrated that this protein binds to apoptotic cells at an early stage, which raises the possibility that it is involved in dealing with apoptotic cells

in vivo. [provided by RefSeq, Sep 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our custom shRNA service.





#### Serum Amyloid P (APCS) Human shRNA Lentiviral Particle (Locus ID 325) - TL316446V

# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).